Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | BACE1 | P56817 | 5/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 1.00 |
| ▸ | MMP7 | P09237 | 5/20 | 1.00 |
| ▸ | MMP14 | P50281 | 5/20 | 1.00 |
| ▸ | BCL2 | P10415 | 4/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | PGAM1 | P18669 | 2/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epigalocatechin Gallate SCHEMBL29389587 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL30977114 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30014282 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30909383 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL10198783 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL14423426 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL35258 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL49461 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL13624466 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL8426376 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087667-A1 | METHOD OF MODIFICATION OF WHEY PROTEIN AT ACIDIC PH BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION | ARLA FOODS AMBA (DK) | 2026-04-30 | — | — | WO | claimed |
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| EP-4701427-A1 | THERMAL ENERGY SYSTEM FOR ADMINISTERING ACTIVE AGENTS | UltraOral Ltd. (IL) | 2026-03-04 | — | — | EP | claimed |
| EP-4697979-A1 | METHOD OF PRODUCING A MODIFIED PROTEIN COMPOSITION BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION | Arla Foods amba (DK) | 2026-02-25 | — | — | EP | claimed |
| EP-4622629-A1 | METHOD FOR TREATING AND/OR PREVENTING EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | Caliway Biopharmaceuticals Co. Ltd. (TW) | 2025-10-01 | — | — | EP | claimed |
| EP-3381451-B1 | PHARMACEUTICAL COMPOSITION USED FOR REDUCING LOCALISED FAT AND USE OF PHARMACEUTICAL COMPOSITION | CALIWAY BIOPHARMACEUTICALS CO LTD (TW) | 2025-08-20 | — | — | EP | claimed |
| CN-115461354-B | Tandem repeat cancer targeting peptides for molecular conjugation or engineering and their use in cancer therapeutic diagnostics | 长庚医疗财团法人林口长庚纪念医院 | 2025-05-09 | — | — | CN | claimed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | claimed |
| WO-2024224392-A1 | THERMAL ENERGY SYSTEM FOR ADMINISTERING ACTIVE AGENTS | ULTRAORAL LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| WO-2024218339-A1 | METHOD OF PRODUCING A MODIFIED PROTEIN COMPOSITION BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION | ARLA FOODS AMBA (DK) | 2024-10-24 | — | — | WO | claimed |
| EP-4210681-A1 | DISSOLVABLE MATRICES | Thorne Healthtech, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| CN-116457022-A | Dissolvable matrix | 索恩健康科技公司 | 2023-07-18 | — | — | CN | claimed |
| EP-4188408-A1 | A STANDARDIZED BIOFLAVONOID COMPOSITION FOR REGULATION OF HOMEOSTASIS OF HOST DEFENSE MECHANISM | Unigen, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| US-11560342-B2 | Bacillus isolates and uses thereof | MONSANTO TECHNOLOGY, LLC (US) | 2023-01-24 | — | — | US | claimed |
| WO-2022243479-A1 | HIGH PROTEIN, MICELLAR CASEIN-CONTAINING NUTRITIONAL LIQUIDS ENRICHED WITH CATECHIN-COMPOUNDS AND METHOD OF PRODUCTION | ARLA FOODS AMBA (DK) | 2022-11-24 | — | — | WO | claimed |
| EP-4057823-A1 | HIGH PROTEIN, MICELLAR CASEIN-CONTAINING NUTRITIONAL LIQUIDS ENRICHED WITH CATECHIN-COMPOUNDS AND METHOD OF PRODUCTION | Arla Foods amba (DK) | 2022-09-21 | — | — | EP | claimed |
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | claimed |
| US-11395814-B2 | Compounds and forms of treatment for female sexual disorders | GTO PHARMA, LLC. | 2022-07-26 | — | — | US | claimed |
| WO-2022055985-A1 | DISSOLVABLE MATRICES | NUTRATIVA LLC (US) | 2022-03-17 | — | — | WO | claimed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560342-B2 | Bacillus isolates and uses thereof | BLVRB, BROX, GLB1 | DYRK1A 2443/4885BACE1 1933/4885MMP2 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.